These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 25387550)

  • 1. The new hepatitis C era: the guidelines are now available, reimbursement not yet..
    Hullegie SJ; Rijnders BJ
    Neth J Med; 2014 Oct; 72(8):386-7. PubMed ID: 25387550
    [No Abstract]   [Full Text] [Related]  

  • 2. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.
    Wörmann B
    Dtsch Arztebl Int; 2017 Jan; 114(1-02):9-10. PubMed ID: 28143634
    [No Abstract]   [Full Text] [Related]  

  • 3. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.
    Geenen JW; Boersma C; Klungel OH; Hövels AM
    Eur J Health Econ; 2019 Aug; 20(6):857-867. PubMed ID: 30953216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Financial burden of hepatitis C infection and its treatment].
    Makara M; Hunyady B
    Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
    Loubière S; Rotily M; Moatti JP
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
    van de Vooren K; Curto A; Garattini L
    Eur J Health Econ; 2015 May; 16(4):341-5. PubMed ID: 25407841
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.
    Brunetto MR; De Luca A; Messori A; Zignego AL
    BMJ; 2015 Jun; 350():h3363. PubMed ID: 26108546
    [No Abstract]   [Full Text] [Related]  

  • 9. [Editorial commentary: Hepatitis C].
    Pár A
    Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy.
    Massad E; Coutinho FA; Chaib E; Burattini MN
    Epidemiol Infect; 2009 Feb; 137(2):241-9. PubMed ID: 18631422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Price of new drugs for hepatitis C: Try to understand the incomprehensible].
    Bergmann JF
    Presse Med; 2015 Sep; 44(9):877-80. PubMed ID: 26453430
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prescription of new HCV-drugs - what has to be considered judicially].
    Mauss S
    Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatitis C therapy: a problem almost solved].
    Rizzetto M
    Recenti Prog Med; 2014 Jun; 105(6):225-6. PubMed ID: 25002283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
    Rubin A; Berenguer M
    Liver Transpl; 2010 Jun; 16(6):697-700. PubMed ID: 20517902
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost effectiveness of direct acting antivirals in the treatment of hepatitis C in vulnerable populations.
    Verma D; Ashkar C; Saab S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):9-12. PubMed ID: 33073620
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis C drug affordability.
    Kamal-Yanni M
    Lancet Glob Health; 2015 Feb; 3(2):e73-4. PubMed ID: 25617196
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.
    Chapko MK; Dominitz JA
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1067-77. PubMed ID: 16984501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C: cost of eradication ].
    Nau JY
    Rev Med Suisse; 2014 Jan; 10(415):306-7. PubMed ID: 24624702
    [No Abstract]   [Full Text] [Related]  

  • 19. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C drugs not reaching poor.
    Callaway E
    Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.